These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 16356553)
1. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. Arias B; Serretti A; Lorenzi C; Gastó C; Catalán R; Fañanás L J Affect Disord; 2006 Feb; 90(2-3):251-6. PubMed ID: 16356553 [TBL] [Abstract][Full Text] [Related]
2. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Benedetti F; Colombo C; Pirovano A; Marino E; Smeraldi E Psychopharmacology (Berl); 2009 Mar; 203(1):155-60. PubMed ID: 18989660 [TBL] [Abstract][Full Text] [Related]
3. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Szegedi A; Rujescu D; Tadic A; Müller MJ; Kohnen R; Stassen HH; Dahmen N Pharmacogenomics J; 2005; 5(1):49-53. PubMed ID: 15520843 [TBL] [Abstract][Full Text] [Related]
4. Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients? Kertzman S; Vainder M; Reznik I; Gotzlav Y; Weizman A; Kotler M; Iancu I Int Clin Psychopharmacol; 2012 May; 27(3):134-41. PubMed ID: 22415223 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Mundo E; Bianchi L; Bellodi L J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005 [TBL] [Abstract][Full Text] [Related]
6. The Catechol-O-methyltransferase Val(108/158)Met Genetic Polymorphism cannot be Recommended as a Biomarker for the Prediction of Venlafaxine Efficacy in Patients Treated in Psychiatric Settings. Taranu A; Asmar KE; Colle R; Ferreri F; Polosan M; David D; Becquemont L; Corruble E; Verstuyft C Basic Clin Pharmacol Toxicol; 2017 Nov; 121(5):435-441. PubMed ID: 28627776 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. Morishita S; Arita S Eur Psychiatry; 2003 Dec; 18(8):418-20. PubMed ID: 14680720 [No Abstract] [Full Text] [Related]
8. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652 [TBL] [Abstract][Full Text] [Related]
9. Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine. Benedetti F; Dallaspezia S; Colombo C; Lorenzi C; Pirovano A; Smeraldi E Eur Psychiatry; 2010 Dec; 25(8):476-8. PubMed ID: 20619611 [TBL] [Abstract][Full Text] [Related]
10. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. Kennedy SH; Andersen HF; Lam RW J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428 [TBL] [Abstract][Full Text] [Related]
12. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to selective serotonin reuptake inhibitors in major depressive disorder. Illi A; Setälä-Soikkeli E; Kampman O; Viikki M; Nuolivirta T; Poutanen O; Huhtala H; Mononen N; Lehtimäki T; Leinonen E Psychiatry Res; 2010 Mar; 176(1):85-7. PubMed ID: 20071037 [TBL] [Abstract][Full Text] [Related]
13. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes. Mitjans M; Gastó C; Catalán R; Fañanás L; Arias B J Psychopharmacol; 2012 Oct; 26(10):1391-8. PubMed ID: 22826533 [TBL] [Abstract][Full Text] [Related]
14. Cloninger's temperament and character dimensions and dopaminergic genes: DAT1 VNTR and COMT Val158Met polymorphisms. Glavina Jelaš I; Dević I; Karlović D Psychiatr Danub; 2018 Mar; 30(1):47-56. PubMed ID: 29546858 [TBL] [Abstract][Full Text] [Related]
15. Association of the COMT val158met variant with antidepressant treatment response in major depression. Baune BT; Hohoff C; Berger K; Neumann A; Mortensen S; Roehrs T; Deckert J; Arolt V; Domschke K Neuropsychopharmacology; 2008 Mar; 33(4):924-32. PubMed ID: 17522626 [TBL] [Abstract][Full Text] [Related]
16. Catechol-O-methyltransferase genotype as modifier of superior responses to venlafaxine treatment in major depressive disorder. Hopkins SC; Reasner DS; Koblan KS Psychiatry Res; 2013 Aug; 208(3):285-7. PubMed ID: 23706899 [TBL] [Abstract][Full Text] [Related]
17. 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. Arias B; Catalán R; Gastó C; Gutiérrez B; Fañanás L J Clin Psychopharmacol; 2003 Dec; 23(6):563-7. PubMed ID: 14624186 [TBL] [Abstract][Full Text] [Related]
18. Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. Vulink NC; Westenberg HG; van Nieuwerburgh F; Deforce D; Fluitman SB; Meinardi JS; Denys D Int J Psychiatry Clin Pract; 2012 Oct; 16(4):277-83. PubMed ID: 22414277 [TBL] [Abstract][Full Text] [Related]
19. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. Tsai SJ; Gau YT; Hong CJ; Liou YJ; Yu YW; Chen TJ J Affect Disord; 2009 Feb; 113(1-2):183-7. PubMed ID: 18533273 [TBL] [Abstract][Full Text] [Related]
20. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]